Hikma Profits on Generic AntiBiotic Sales

The Telegraph reported that Hikma Pharmaceuticals (LSE:HIK) gained over 45 percent this year and first-half results beat market expectations.

As quoted in the market news:

Hikma has enjoyed bumper sales in the US of a generic antibiotic called doxycycline, used to prevent malaria and other infections. That has resulted in full-year guidance being raised for the third time in four months. Hikma now expects total revenue to rise 20pc in 2013, up from 17pc previously.

Click here for the full article on The Telegraph